Public-Private Mix for TB Care and Control

Report of the Seventh Meeting of the Subgroup on Public-Private Mix for TB Care and Control

Lille, France
23-24 October 2011
Public–private mix for TB care and control

Report of the seventh meeting of the Subgroup on Public–Private Mix for TB care and control

Lille, France
23-24 October 2011
Acknowledgement

This study/report/audio/visual/other information product is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of TB CARE I and not necessarily reflect the views of USAID or the United States Government.

© World Health Organization 2012

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication does not necessarily represent the decisions or policies of the World Health Organization.
# Contents

Abbreviations  iv

1. Introduction  1

2. Objectives and expected outcomes  3
   2.1 Objectives  3
   2.2 Expected outcomes  3

3. Summary of presentations and discussions  4

4. Recommendations  5

Appendix 1. Meeting agenda  11
Appendix 2. List of participants  13
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACSM</td>
<td>Advocacy, Communication and Social Mobilization</td>
</tr>
<tr>
<td>DEWG</td>
<td>DOTS Expansion Working Group</td>
</tr>
<tr>
<td>DOTS</td>
<td>The internationally recommended strategy for TB control</td>
</tr>
<tr>
<td>FHI</td>
<td>Family Health International</td>
</tr>
<tr>
<td>GDF</td>
<td>Global Drug Facility</td>
</tr>
<tr>
<td>GLI</td>
<td>Global Laboratory Initiative</td>
</tr>
<tr>
<td>Global Fund</td>
<td>Global Fund to Fight AIDS, Tuberculosis and Malaria</td>
</tr>
<tr>
<td>HBC</td>
<td>high TB-burden country</td>
</tr>
<tr>
<td>HDL</td>
<td>hospital DOTS linkage</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>human immunodeficiency virus/acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>HRD</td>
<td>Human Resource Development</td>
</tr>
<tr>
<td>ISTC</td>
<td>International Standards for Tuberculosis Care</td>
</tr>
<tr>
<td>JATA</td>
<td>Japan Anti-Tuberculosis Association</td>
</tr>
<tr>
<td>KNCV</td>
<td>Royal Netherlands TB Association</td>
</tr>
<tr>
<td>MDG</td>
<td>Millennium Development Goal</td>
</tr>
<tr>
<td>MDR-TB</td>
<td>multidrug-resistant tuberculosis</td>
</tr>
<tr>
<td>MSH</td>
<td>Management Sciences for Health</td>
</tr>
<tr>
<td>NGO</td>
<td>nongovernmental organization</td>
</tr>
<tr>
<td>NTP</td>
<td>national tuberculosis control programme</td>
</tr>
<tr>
<td>PEPFAR</td>
<td>The US President's Emergency Plan for AIDS Relief</td>
</tr>
<tr>
<td>PP</td>
<td>private provider</td>
</tr>
<tr>
<td>PPM</td>
<td>public–private mix</td>
</tr>
<tr>
<td>PPM Subgroup</td>
<td>Subgroup on Public–Private Mix for TB care and control</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TBCAP</td>
<td>Tuberculosis Control Assistance Programme</td>
</tr>
<tr>
<td>The Union</td>
<td>International Union against Tuberculosis and Lung Disease</td>
</tr>
<tr>
<td>USAID</td>
<td>United States Agency for International Development</td>
</tr>
<tr>
<td>WHA</td>
<td>World Health Assembly</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>XDR-TB</td>
<td>extensively drug-resistant tuberculosis</td>
</tr>
</tbody>
</table>
1. Introduction

Engaging all care providers in TB care and control through public–private mix (PPM) approaches and promoting the International Standards for Tuberculosis Care (ISTC) are among the core components of the global Stop TB Strategy. Strengthening health systems through the involvement of all relevant health-care providers outside the national TB programmes (NTPs) is essential to meet the TB-related Millennium Development Goals and reach the targets for tuberculosis (TB) control set out in the Global Plan to Stop TB 2006–2015. The Stop TB Partnership’s Subgroup on Public–Private Mix for TB Care and Control (PPM Subgroup) has been instrumental in assisting countries to enhance collaboration among diverse public, private, voluntary and corporate care providers to improve access to high-quality TB care to all who need it.

The seventh meeting of the PPM Subgroup, supported by the TB CARE Program of the United States Agency for International Development (USAID), was organized in Lille, France, on 23 and 24 October 2011.

The seventh meeting was organized at a critical juncture with several countries implementing scaled-up PPM programmes and reporting contribution of PPM to TB case notifications for publication in WHO’s annual global TB control report. However, a large proportion of non-programme public, voluntary, private and corporate care providers still remain unlinked to national TB programmes. Large scale misuse of TB medicines outside TB programmes has not declined and few countries have embarked on complementary approaches such as mandatory case notification, accreditation of care providers or addressing irrational use of TB medicines. New TB diagnostics such as
line probe assays and Gene Xpert have been introduced and new TB drugs are on the horizon. Taking stock of the significant global, regional and country level progress on PPM expansion since the last meeting, the 7th meeting reviewed country approaches to regulate irrational use of TB medicines and discuss how PPM programmes can facilitate introduction and expansion of new diagnostics and new drugs to non-programme care providers. Further, taking into account the ongoing restructuring of the Working Groups of the Stop TB Partnership, the meeting also addressed key components of a biennial action plan that could help a potential new structure to continue addressing engagement of all care providers in TB care and control.

This report summarizes the proceedings of the seventh meeting. The objectives and expected outcomes are presented in Section 2. Section 3 briefly outlines the presentations and discussions at the meeting, while the fourth section lists the major conclusions and recommendations.
2. Objectives and expected outcomes

2.1 Objectives

1. To review the global and regional progress on PPM;
2. To share processes and outcomes of PPM scale up by national TB programmes in Asia and Africa;
3. To discuss the potential of PPM in the introducing new diagnostics and new drugs for TB;
4. To identify key components and activities of a biennial global action plan on engaging all care providers through PPM approaches.

2.2 Expected Outcomes

1. A review of global, regional and working examples of national progress in scaling up engagement of all care providers through PPM approaches;
2. Possible ways to use PPM platforms to introduce new diagnostics and new TB drugs and ways to promote their rational use;
3. Identification of key components and activities of a biennial global action plan on engaging all care providers through PPM approaches;
4. Recommendations for sustaining and expanding work on PPM for TB care and control.
3. Summary of presentations and discussions

The presentations, discussions and in-depth deliberations in break-out groups over the two days covered a wide range of topics. These included: overall progress in PPM implementation from global, regional and country perspectives; innovative initiatives such as engaging pharmacists in TB care and control and country experiences with ensuring rational use of TB drugs; and implications of introduction of new diagnostics and new drugs for TB for PPM. Ways to harnessing resources for PPM expansion and a comprehensive “white paper” on “increasing the effectiveness of the Stop TB Partnership in engaging all care providers” were also discussed. Facilitated by area experts, the participants formed small groups to discuss actions required under four specific areas: strengthening country capacity for PPM scale up, engaging pharmacists in TB care and control, using PPM programmes for introducing new diagnostics and drugs and strengthening advocacy and surveillance for PPM.

To access meeting presentations please click on this link,
4. Recommendations

The meeting concluded with full agreement on the following recommendations:

To the DOTS Expansion Working Group and the Stop TB Coordinating Board:

1. **Accord the PPM Subgroup full Working Group status (or equivalent in the new structure).** Engaging all care providers through context-specific PPM approaches is widely accepted now as integral and essential to achieving universal access to quality TB care. Successive global TB control reports have shown significant and increasing contribution of non-programme care providers to TB care and control. The need and potential of further PPM scale up to help address stagnating case notifications and slow decline in TB incidence are very clear. PPM approaches should also be incorporated into other components of the Stop TB Strategy including programmatic management of MDR-TB, collaborative TB/HIV activities, operational research on the introduction and uptake of new diagnostics and drugs, and ACSM (Advocacy, Communication and Social Mobilization) strategies. In the restructuring of Stop TB Partnership’s Working Groups currently under way, according the PPM Subgroup full Working Group status would help accelerate expanding access to quality TB care through PPM scale up and enable achieving much needed mainstreaming of PPM into the various components of the Stop TB Strategy.

2. **Communicate effectively to Stop TB Partners and NTPs the PPM approaches with proven impact on TB care and control.** Evidence from PPM scale up in diverse country settings shows that significant increase in case notifications while maintaining high treatment success rates is achievable by prioritizing engagement of
large hospitals and large faith-based and non-governmental organizations. Country experiences also indicate that productive involvement of private practitioners is greatly facilitated by entrusting the task of engaging them to intermediary agencies such as professional associations and social franchising organizations. There is also a need to prioritize workplace TB programmes.

3. Disseminate the WHO/FIP Joint Statement widely and promote engagement of pharmacy associations and drug regulatory bodies in national partnerships to Stop TB. Pharmacists have been shown to contribute to TB care and control in various ways including early referral of TB symptomatics, treatment support and ensuring rational use of TB drugs. Enhancing the engagement of pharmacists will require: monitoring and evaluation of working approaches to engage pharmacists, compiling and disseminating country experiences on best practices. Contribution of pharmacists to TB care and control should be highlighted in the global TB report. Pharmacy engagement should be undertaken in an integrated, health systems approach that also incorporates TB care and control.

4. Track sale and use of new diagnostics in public and private sectors in collaboration with national authorities and manufacturers. Availability of new diagnostic tests for TB such as geneXpert MTB/RIF has opened up new possibilities to strengthen and expand collaboration between the public and private sectors. Tracking sale of new machines and cartridges in the private sector should go hand in hand with ensuring recommended protocols for diagnosis and treatment of TB and drug-resistant TB. For this purpose, a coordinated approach to set up collaboration among NTPs, the manufacturers, private sector laboratories and care providers is recommended.

5. Develop the public health case for protecting new TB drugs from irrational use and work with stakeholders to identify channels through which new TB drugs should be made available. Evidence shows that large quantities of TB drugs are misused outside NTPs especially in countries with a large private sector. Irrational use of TB drugs leads to emergence and spread of drug-resistant TB. In order for them to remain effective, new TB drugs need to be protected from potential irrational use. It is important therefore to develop the public health case on the extent to which sales, distribution, prescription and dispensing rights for new TB drugs should be restricted.
Furthermore, it is also essential to determine effective ways of ensuring rational use and wide availability of new TB drugs. This will require all stakeholders including NTPs, regulatory authorities, and drug manufacturers working closely together to address the issue.

6. **Advise ways to secure and sustain resources for PPM scale up.** In view of the likelihood of fewer resources being available to scale up and sustain PPM programmes, countries need to be advised and assisted to secure funding through available and new TB-specific resources as well as those available for multi-sectoral, integrated initiatives.

**To National TB Programmes / Ministries of Health**

1. **Prioritize scaling up PPM and ensure documentation and reporting of contributions of non-programme care providers.** The global TB report of 2011 shows that non-programme public and private care providers contributed about 20% to 40% of the notified TB cases in 20 countries including 10 high TB-burden countries. A general observation however has been that the proportion of private care providers actively collaborating with NTPs still remains modest. In order to detect all TB cases and detect them early, NTPs need to prioritize scaling up engagement of private formal and informal care providers. Further, in some instances, NTPs do not report cases managed by long-term partners such as faith-based organizations, academic institutions or corporate health institutions under PPM contributions. In order to both determine and acknowledge input from all collaborating health facilities and to facilitate standardized reporting across countries, NTPs should ensure that records related to referral, diagnosis and treatment of TB cases by all non-programme care providers are maintained, analyzed and reported at the national as well as global levels.

2. **Intensify engagement of large hospitals to improve case notifications and treatment success of large proportions of people with TB presenting to hospitals.** In many countries a large proportion of TB symptomatics and cases present themselves to

---

1 For one country viz. India, the reported contribution was from 14 large cities covering 50 million population only, where a PPM surveillance system is in place
and are managed in large hospitals. Evidence from some settings shows that significant proportions of these cases are not managed according to national or international recommendations and are not notified. Setting up mechanisms for interdepartmental coordination within hospitals and linkages with peripheral public and private health facilities for referral and follow up has been shown to help increase case notification and improve care.

3. **Consider using intermediary agencies to scale up engagement of formal and informal private practitioners.** While engaging solo private practitioners has been shown to increase early case detection, working with a large number of formal and informal private practitioners, training and orienting them, supervising them and providing them adequate support poses challenges for NTPs. Experiences in several countries have shown that intermediary agencies such as social franchising organizations, non-governmental organizations and professional associations can be very effective in engaging private practitioners in TB care and control.

4. **Adapt and implement the WHO/FIP joint statement on the role of pharmacists in TB care and control.** Pharmacists are the first point of contact for many people with symptoms of TB and have been shown to contribute to TB care and control in various ways including, for example, early identification and referral of TB symptomatics. The recently launched statement on the role of pharmacists in TB care control jointly by WHO and the International Pharmaceutical Federation describes how pharmacists can collaborate with TB programmes and urges NTPs and national pharmacy associations to work together to tap the potential of pharmacists in enhancing early case detection and improving TB treatment and care.

5. **Secure resources through TB specific and multi-sectoral channels to help scale up PPM programmes.** In many countries PPM initiatives are being implemented with support from external project-based funding. Scaling up and sustaining PPM programmes will require continued availability of resources. In preparing for a potential shortfall in the availability of external finances, NTPs should secure funding to sustain and expand PPM initiatives not only through traditional channels but also multi-sectoral and multi-programme initiatives designed to achieve synergy and improve efficiency.
6. **Strengthen the system for monitoring of importation of new diagnostics and set up a system of quality assurance, regulation and accreditation for the users of new diagnostics.** Introduction of new tests such as geneXpert MTB/RIF for the diagnosis of TB and drug-resistant TB will increase the monitoring responsibilities of NTPs. NTPs should use the opportunity not only to strengthen their own system of laboratory quality assurance but also to monitor sale of the new machines in the private sector and institute methods for certifying and accrediting private providers using new diagnostics. Further, NTPs should also ensure that all patients diagnosed as TB receive appropriate treatment and care.

7. **Work with drug regulatory authorities and other stakeholders to address availability new TB drugs to non-programme care providers and ensure their rational use.** Considering global evidence on massive misuse of first-line TB drugs in the private market in many high TB-burden countries, NTPs should be alert as to how the “precious few” new TB drugs when available, will be made accessible to and used appropriately in the private market. In collaboration with stakeholders including drug manufacturers, drug regulatory authorities, pharmacy associations, civil society and Stop TB partners, NTPs should assess the extent to which the availability of new TB drugs to the private sector should or should not be restricted and ways of effectively enforcing any restriction.

**To the PPM Subgroup Secretariat**

1. **Support documentation and dissemination of innovative and effective PPM approaches being implemented in diverse country settings and facilitate scaling up of successful initiatives.** The PPM Subgroup secretariat, advised by the PPM Core Group, should coordinate documentation and dissemination of innovative approaches such as engaging pharmacists in TB care and control, diverse PPM-related interventions being implemented within TB REACH supported projects and introducing new diagnostics and drugs in the private sector.

2. **Pursue strategies and activities outlined in the white paper on engaging all care providers to increase effectiveness of the Stop TB Partnership.** The white paper
lists clear objectives and strategies to further PPM expansion and the PPM tool-kit provides the tools to help implement many of the strategies outlined.

3. **Continue supporting countries to strengthen and improve PPM implementation including surveillance.** Precise data on the contribution of PPM initiatives to TB control have now been reported in two successive reports on global TB control. It is important to ensure that there is continuity in this reporting. The Secretariat should follow up and help produce PPM specific data for the global TB report from an increasing number of countries.
## Appendix 1.

### Agenda

23 October 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Session I: Introduction</th>
<th>Chair: Phil Hopewell</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 - 9:00</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>9:00 - 9:10</td>
<td>Welcome, objectives and agenda</td>
<td>Phil Hopewell</td>
</tr>
<tr>
<td>9:10 - 9:15</td>
<td>Opening remarks</td>
<td>M Raviglione / D Weil</td>
</tr>
<tr>
<td>9:15 - 9:30</td>
<td>Discussion on the meeting agenda</td>
<td>All</td>
</tr>
</tbody>
</table>

### Session II: Panel: Global and regional progress  Chair: Cheri Vincent

<table>
<thead>
<tr>
<th>Time</th>
<th>Session II: Panel: Global and regional progress</th>
<th>Chair: Cheri Vincent</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 - 10:00</td>
<td>Global progress and issues</td>
<td>Mukund Uplekar</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Panel discussion: Regional perspectives</td>
<td>Regional Advisors / their representatives: AFR, AMR, EMR, EUR, SEAR, WPR</td>
</tr>
</tbody>
</table>

**COFFEE 10:30 – 10:45**

### Session III: Spotlight: Country progress  Chair: D’Arcy Richardson

<table>
<thead>
<tr>
<th>Time</th>
<th>Session III: Spotlight: Country progress</th>
<th>Chair: D’Arcy Richardson</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 11:15</td>
<td>Scaling up PPM in Nigeria</td>
<td>J Obasanya</td>
</tr>
<tr>
<td>11:15 - 11:45</td>
<td>Scaling up PPM in Indonesia</td>
<td>D Mustikaveti</td>
</tr>
<tr>
<td>11:45 - 12:15</td>
<td>Scaling up PPM in Myanmar</td>
<td>Thandar Lwin</td>
</tr>
<tr>
<td>12:15 - 12:30</td>
<td>Social franchising for TB care: global experience</td>
<td>May Sudhinaraset</td>
</tr>
</tbody>
</table>

**LUNCH 12:30 – 13:30**

### Session IV: Innovative approaches  Chair: S Egwaga

<table>
<thead>
<tr>
<th>Time</th>
<th>Session IV: Innovative approaches</th>
<th>Chair: S Egwaga</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 – 14:00</td>
<td>Systematic approach to engaging hospitals: Philippine experience</td>
<td>L Vianzon</td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Engaging pharmacies: country experiences</td>
<td>D’Arcy Richardson</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>WHO-FIP joint statement on role of pharmacists in TB care and control</td>
<td>Xuanhao Chan and Monica Dias</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td>Rational use of TB drugs: country approaches</td>
<td>Mukund Uplekar</td>
</tr>
</tbody>
</table>

**COFFEE 15:15 – 15:30**

### Session V: New tools and approaches  Chair: L Vianzon

<table>
<thead>
<tr>
<th>Time</th>
<th>Session V: New tools and approaches</th>
<th>Chair: L Vianzon</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 16:00</td>
<td>New TB drugs and the private market</td>
<td>William Wells</td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>Gene Xpert and the private sector</td>
<td>Evan Lee</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td>PPM in TB REACH</td>
<td>S Sahu</td>
</tr>
<tr>
<td>Time</td>
<td>Session VI: The future of PPM: Resources and Strategies</td>
<td>Chair: J Voskens</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>9:00 - 9:15</td>
<td>Tapping resources and promoting tools for PPM</td>
<td>C Vincent</td>
</tr>
<tr>
<td>9:15 - 9:30</td>
<td>PPM and the Global Fund</td>
<td>SS Lal</td>
</tr>
<tr>
<td>9:30 - 10:00</td>
<td>White Paper on the future of PPM</td>
<td>P Hopewell</td>
</tr>
</tbody>
</table>

**COFFEE 10:00 – 10:30**

**Session VII: Group work: PPM Subgroup Action Plan**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Chair:</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:45</td>
<td>Guidance on proposed group work</td>
<td>K Lönnroth</td>
</tr>
<tr>
<td>10:45 - 12:30</td>
<td>Group Work</td>
<td></td>
</tr>
</tbody>
</table>

**LUNCH 12:30 – 13:30**

**Plenary**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Chair:</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td>Reporting back by groups</td>
<td>J M Chakaya</td>
</tr>
</tbody>
</table>

**COFFEE 15:00 – 15:30**

**Session VIII: Conclusions and recommendations**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Chair:</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 17:00</td>
<td>Conclusions and recommendations</td>
<td>P Hopewell</td>
</tr>
<tr>
<td>17:00</td>
<td>Closing remarks</td>
<td>M Uplekar</td>
</tr>
</tbody>
</table>
Appendix 2.

List of participants

COUNTRY REPRESENTATIVES

AFRICAN REGION

DEMOCRATIC REPUBLIC OF CONGO
Dr Jean-Paul Okiata
National TB Programme Manager
Ministry of Health
4310 Boulevard du 30 juin
B.P. 3088 Kin 1
Kinshasa Gombé

GHANA
Dr Frank Adae Bonsu
National TB Programme Manager
Disease Control Unit
P.O. Box KB 493
Korle Bu
Accra

KENYA
Dr Jeremiah Muhwa Chakaya
Chief Research Officer
Centre for Respiratory Diseases
Research
Kenya Medical Research Institute
P.O. Box 47855
Nairobi, 00100

NIGERIA
Dr J.O. Obasanya
National TB Programme Manager
Federal Ministry of Health
Department of Public Health
N°2 Justice Sowemimo street.
Asokoro
Abuja

Dr Labaran Shehu
PPM Focal Point
Federal Ministry of Health
Department of Public Health
N°2 Justice Sowemimo street.
Asokoro
Abuja

SWAZILAND
Dr Themba Dlamini
National TB Programme Manager
P.O. Box 54
Manzini

DEMOCRATIC REPUBLIC OF TANZANIA
Dr Saidi M. Egwaga
National TB Programme Manager
EASTERN MEDITERRANEAN REGION

PAKISTAN
Dr Ejaz Qadeer
National TB Control Programme Manager
Zakia Aziz Plaza
Fazle-Haq Road
Islamabad
Pakistan

SOUTH-EAST ASIA REGION

BANGLADESH
Dr Md. Ashaque Husain, Director-MBDC & Line Director-TB/Leprosy
National Tuberculosis Control Programme (NTP)
Leprosy Hospital Compound, DGHS, TB Gate, Mohakhali, Dhaka-1212

MYANMAR
Dr Thandar Lwin
National TB Programme Manager
National TB Control Programme
Department of Health
Ministry of Health
Nay Pyi Taw

INDONESIA
Drg Dyah Erti Mustikawati
National TB Programme Manager
Ministry of Health
Directorate General Disease Control and Environmental Health
Jalan Percetakan Negara No 29
Jakarta Pusat 10560
PO Box 223

THAILAND
Dr Krisada Mahotarn
Director of Tuberculosis Bureau
Department of Disease control
MOPH

Dr Asik
Head of Monitoring and Evaluation of NTP Indonesia
Ministry of Health
Directorate General Disease Control and Environmental Health
Jalan Percetakan Negara No 29
Jakarta Pusat 10560

Mr Booncherd Kladphuang
Public Health Technical Officer
Senior Professional level
PPM focal point
Tuberculosis Bureau
Department of Disease control
MOPH
WESTERN PACIFIC REGION

CAMBODIA
Dr Mao Tan Eang
Director
278/95 Sangkat Boeung Keng Kang II
Khan Chamcar Mon
Phnom Penh

PHILIPPINES
Dr Rosalind Vianzon
TB Unit, Infectious Diseases Office
National Centre for Disease Prevention
And Control
Department of Health
Bldg 13, San Lazaro Compound
Rizal Avenue, Sta Cruz
Manila

PARTNER REPRESENTATIVES

AMERICAN THORACIC SOCIETY
Dr Philip Hopewell
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
San Francisco General Hospital Room 5K1
San Francisco, CA 94110
USA

THE GLOBAL FUND
Dr S.S. Lal
Senior Technical Officer
Strategy, Performance and Evaluation
The Global Fund to Fight AIDS Tuberculosis and Malaria
8, chemin de Blandonnet
1214 Vernier
Geneva
Switzerland

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT
Dr Williams Wells
TB Alliance
40 Wall St 24th Floor
New York, NY 10005
USA

Ms Elizabeth Gardiner
Vice-President, Market Access
Global Alliance for TB Drug Development
40 Wall Street, 24th Floor
10005 - New York, NY
USA

GLOBAL LABORATORY INITIATIVE (GLI)
Evan Lee
Foundation for Innovative New Diagnostics
16 avenue de Bude
Geneva, Switzerland

JAPAN ANTI TUBERCULOSIS ASSOCIATION
Dr Shimouchi Akira
Senior Researcher, Department of Epidemiology and Clinical Research
The Research Institute of TB Japan Anti-Tuberculosis Association
Matsuyama 3-1-24
Kiyose 204-8533
Tokyo
Japan
Dr Akihiro Okado  
Japan Anti-Tuberculosis Association  
Matsuyama 3-1-24  
Kiyose 204-8533  
Tokyo  
Japan  

KNCV TUBERCULOSIS FOUNDATION  
Dr Jan Voskens  
Senior Consultant  
International Unit  
KNCV Tuberculosis Foundation  
Parkstraat 17, The Hague  
The Netherlands  

Dr Netty Kamp  
Senior Consultant Tuberculosis  
KNCV Tuberculosis Foundation  
Parkstraat 17, The Hague  
The Netherlands  

LHL  
Dr Rasmus Malmborg  

MSH  
Dr Pedro Suarez  
4301 North Fairfax Drive  
Suite 400  
Arlington, Virginia 22203  
USA  

PATH  
Dr D'Arcy Richardson  
Technical Officer  
HIV and TB Global Programme  
PATH  
1800 K. Street NW  
Suite 800  
Washington, D.C., 20006  
USA  

REACH  
Dr Nalini Krishnan  
Kasturi and Sons Ltd and REACH  
The Hindu  
859, Anna Salai  
Chennai 600002  
India  

GLOBAL HEALTH, USCF  
May Sudhinaraset  

UNIVERSITY OF MANITOBA  
Dr Earl Samuel Hershfield  
Respiratory Medicine  
University of Manitoba  
810 Sherbrook St.  
R3A 1R8 - Winnipeg, MB  
Canada  

UNIVERSITY RESEARCH CORPORATION  
Dr Perla Isagari  
8208 Cottage Street  
Vienna, VA  
USA  

USAID  
Dr Cheri Vincent  

WEF  
Dr Shaloo Puri Kamble  
Head  
India Business Alliance and Advisor  
C 732 Sushant Lok 1  
Gurgaon  
Haryana  
India
PRIVATE SECTOR REPRESENTATIVE

STB Partnership
Dr Herbert Schilthuis
Heineken International Health Affairs
2e Weteringplantsoen 21
Amsterdam
The Netherlands

WHO SECRETARIAT

AFRICAN REGION
Dr Bah-Keita
Regional Adviser TB
WHO Regional Office for Africa
Brazzaville
Congo

Dr Daniel Kibuga
Medical Officer
WHO Regional Office for Africa
Brazzaville
Congo

Dr Richard Mbumba
National Professional Officer
DRC

Dr Sally Ann Ohene
National Professional Officer
TB Focal Point
The Office of the WHO Representative
Accra
Ghana

Mr Kefas Samson
Medical Officer
The Office of the WHO Representative
Mbabane
Swaziland

EUROPEAN REGION
Dr Masoud Dara
Regional Adviser
WHO Regional Office for Europe
Kobenhavn
Danemark

SOUTH-EAST ASIA REGION
Dr Khurshid Alam Hyder
Acting TB Regional Adviser
Regional Adviser, TB
WHO Regional Office for South-East Asia
New Delhi
India

Dr Erwin Cooreman
Medical Officer
WHO Regional Office for South-East Asia
New Delhi
India

Doctor Vikarunnessa Begum
NPO
WR Office, Bangladesh
Dhaka
Bangladesh
Dr Mohamed Akhtar
Medical Officer, TB
The Office of the WHO Representative
Kathmandu
Nepal

WESTERN PACIFIC REGION
Dr Woojin Lew
Medical Officer for Stop TB and Leprosy Elimination
WHO Regional Office for Western Pacific Manila Philippines

Dr Nobuyuki Nishikiori
Medical Officer, Stop TB
WHO Regional Office for Western Pacific Manila Philippines

Dr Mariquita J. Mantala
National Professional Officer
The Office of the WHO Representative Building 3, Department of Health San Lazaro Compound, Sta Cruz Manila Philippines

Jiang Shiwen
WHO China

Dr Pham Huyen Khanh
National Professional Officer
The Office of the WHO Representative Hanoi Viet Nam

WHO HEADQUARTERS
Ms Hannah Monica Dias
Technical Officer, STB/TBS

Dr Knut Lönroth
Medical Officer, STB/TBS

Dr Suvanand Sahu
Medical Officer, TB REACH

Dr Mukund Uplekar
Medical Officer, STB/TBS

Dr Diana Weil
Coordinator, Policy, Strategy and Innovations
Four useful tools for PPM planning, implementation and advocacy

"The PPM toolkit"

"The PPM Guidance Document"

"The National Situation Assessment tool"

These and other PPM documents can be downloaded from the PPM homepage at:

www.who.int/tb/careproviders/ppm

For further information, please contact
Stop TB Department
World Health Organization
20 Avenue Appia • CH-1211 Geneva 27 • Switzerland
Telephone +41 22 791 2111 • Facsimile +41 22 791 4199

Stop TB department website
www.who.int/tb